Sassine Ghanem1, Sami Hossri2, Nicholas Fuca3, Evgenia Granina4, Samer Saouma5, Frank Forte6. 1. Department of Hematology and Medical Oncology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY, USA. sassine.ghanem@downstate.edu. 2. Department of Pulmonary and Critical Care, Northwell Health - Staten Island University Hospital, Staten Island, NY, USA. 3. Department of Nephrology, Mount Sinai, New York, NY, USA. 4. Department of Hospice and Palliative Care Medicine, Virginia Commonwealth University, Richmond, VA, USA. 5. Department of Cardiology, Northwell Health - Staten Island University Hospital, Staten Island, NY, USA. 6. Department of Hospice and Palliative Care Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY, USA.
Abstract
PURPOSE: The 1-year mortality rate of patients with end-stage renal disease (ESRD) on renal replacement therapy (RRT) is 20-25% comparable to many cancers. Studies have shown that cancer patients commonly overestimate their likelihood of survival relative to their physicians. It is unclear if this translates into other terminal illnesses. METHODS: Adult and elderly patients with ESRD on RRT without cognitive defect were interviewed to evaluate their prognostic estimates at 1 and 5 years. Past medical history and demographic data was abstracted from their medical charts. Each patient's proper nephrologist was then interviewed regarding his proper prognostic estimate for this patient. Both the patient and the nephrologist's estimates were compared and a difference of greater than 20% was defined as the threshold for prognostic concordance. RESULTS: 77% of patients were found to be in prognostic discordance with their nephrologists. This group was older, had more comorbidities, a lower albumin level and a poorer prognosis. The majority of patients were in disagreement with their nephrologists regarding whether a discussion about prognosis had taken place. The choice of end of life care for 55% of patients was focused on relieving pain and discomfort. CONCLUSION: Communication of prognosis and discussions related to life expectancy and end of life care are lacking in the routine care of ESRD patients. ESRD patients therefore tend to overestimate their prognosis which might lead to overutilization of invasive procedures with increased acute healthcare costs as well as a delay in instigation of palliative or hospice measures.
PURPOSE: The 1-year mortality rate of patients with end-stage renal disease (ESRD) on renal replacement therapy (RRT) is 20-25% comparable to many cancers. Studies have shown that cancerpatients commonly overestimate their likelihood of survival relative to their physicians. It is unclear if this translates into other terminal illnesses. METHODS: Adult and elderly patients with ESRD on RRT without cognitive defect were interviewed to evaluate their prognostic estimates at 1 and 5 years. Past medical history and demographic data was abstracted from their medical charts. Each patient's proper nephrologist was then interviewed regarding his proper prognostic estimate for this patient. Both the patient and the nephrologist's estimates were compared and a difference of greater than 20% was defined as the threshold for prognostic concordance. RESULTS: 77% of patients were found to be in prognostic discordance with their nephrologists. This group was older, had more comorbidities, a lower albumin level and a poorer prognosis. The majority of patients were in disagreement with their nephrologists regarding whether a discussion about prognosis had taken place. The choice of end of life care for 55% of patients was focused on relieving pain and discomfort. CONCLUSION: Communication of prognosis and discussions related to life expectancy and end of life care are lacking in the routine care of ESRDpatients. ESRDpatients therefore tend to overestimate their prognosis which might lead to overutilization of invasive procedures with increased acute healthcare costs as well as a delay in instigation of palliative or hospice measures.
Entities:
Keywords:
End stage renal disease; Hemodialysis; Prognosis; Quality of life
Authors: Rajiv Saran; Yi Li; Bruce Robinson; Kevin C Abbott; Lawrence Y C Agodoa; John Ayanian; Jennifer Bragg-Gresham; Rajesh Balkrishnan; Joline L T Chen; Elizabeth Cope; Paul W Eggers; Daniel Gillen; Debbie Gipson; Susan M Hailpern; Yoshio N Hall; Kevin He; William Herman; Michael Heung; Richard A Hirth; David Hutton; Steven J Jacobsen; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Yee Lu; Miklos Z Molnar; Hal Morgenstern; Brahmajee Nallamothu; Danh V Nguyen; Ann M O'Hare; Brett Plattner; Ronald Pisoni; Friedrich K Port; Panduranga Rao; Connie M Rhee; Ankit Sakhuja; Douglas E Schaubel; David T Selewski; Vahakn Shahinian; John J Sim; Peter Song; Elani Streja; Manjula Kurella Tamura; Francesca Tentori; Sarah White; Kenneth Woodside; Richard A Hirth Journal: Am J Kidney Dis Date: 2016-03 Impact factor: 8.860
Authors: Mae Thamer; James S Kaufman; Yi Zhang; Qian Zhang; Dennis J Cotter; Heejung Bang Journal: Am J Kidney Dis Date: 2015-06-26 Impact factor: 8.860
Authors: Melissa W Wachterman; Edward R Marcantonio; Roger B Davis; Robert A Cohen; Sushrut S Waikar; Russell S Phillips; Ellen P McCarthy Journal: JAMA Intern Med Date: 2013-07-08 Impact factor: 21.873
Authors: Robert A Cohen; Vicki A Jackson; Diana Norwich; Jane O Schell; Kristen Schaefer; Amy N Ship; Amy M Sullivan Journal: Am J Kidney Dis Date: 2016-03-16 Impact factor: 8.860
Authors: Manjula Kurella Tamura; Kenneth E Covinsky; Glenn M Chertow; Kristine Yaffe; C Seth Landefeld; Charles E McCulloch Journal: N Engl J Med Date: 2009-10-15 Impact factor: 91.245